Cardiopulmonary Bypass in Cyanotic Patients — Key Principles

Cyanotic infants and children reach the operating room with adaptive physiology—polycythemia, enlarged systemic-to-pulmonary collateral beds, and cerebrovascular autoregulation conditioned by low PaO₂ and modestly elevated PaCO₂. These adaptations alter responses to cardiopulmonary bypass (CPB). Across studies and reviews, two themes consistently emerge: (1) avoid extreme hemodilution and abrupt “normalization” of blood gases, and (2) favor adequate oxygen delivery via higher flows and sufficient hematocrit while using neuromonitoring to titrate in real time [1, 2]. Contemporary pediatric data also caution against hyperoxia on CPB, which is associated with harm in infants [3].

1) Blood-gas management (avoid abrupt “normalization”)

Principle. Chronic hypoxemia promotes systemic/cerebral vasodilation. If PaO₂ is abruptly driven high and PaCO₂ rapidly lowered at CPB initiation, cerebral vasoconstriction and reduced cerebral blood flow can follow. Normalize deliberately and stepwise, guided by cerebral NIRS and arterial pressure, accepting modest hypoxemia and mild hypercarbia early on CPB before titrating sweep gas and FiO₂ to final targets.

What to do.

• Begin with controlled reoxygenation (normoxia strategy) rather than immediate hyperoxia; randomized pediatric data show normoxia reduces oxidative-stress biomarkers and is feasible/safe in cyanotic cohorts [4].
• Adjust PaCO₂ gradually; cerebral blood flow (CBF) in children on hypothermic CPB varies with temperature and pressure, and CO₂ remains a potent cerebrovascular modulator [5].
• Track right/left rSO₂ and venous saturation; trend-based decisions are more reliable than single values.

Why it matters. Avoiding abrupt gas shifts helps maintain CBF and mitigates oxidative/reperfusion injury—priorities in cyanotic neonates/infants with limited reserve [1, 4–5].

2) Systemic-to-pulmonary collateral “steal”

Principle. Robust aortopulmonary (AP) collaterals (e.g., TOF/PA ± MAPCAs) siphon pump flow into the lungs, jeopardizing effective systemic perfusion and pressure. Anticipate higher pump flows than weight alone would suggest.

What to do.

• Tolerate slightly higher PaCO₂ on bypass to increase PVR and blunt collateral runoff (while monitoring cerebral/organ perfusion).
• Maintain age-appropriate MAP with vasoactive support as needed to protect systemic beds.
• When feasible (e.g., MAPCA unifocalization), control or ligate collateral sources early during bypass to reduce runoff and improve perfusion pressure [7, 8].

Why it matters. Residual collateral flow can be substantial and may require pump-flow adjustments to assure systemic perfusion [7, 8]. +

3) Pulmonary venous return and LV distension

Principle. Chronic cyanosis/collaterals increase pulmonary venous return even on CPB. Without venting, the left atrium/ventricle distend, impairing myocardial protection and elevating pulmonary venous pressures.

What to do.

• Place and confirm an effective LA/LV vent early; reassess throughout cooling, repair, and rewarming.
• Combine with gentle myocardial protection and vigilant de-airing during transitions.

Why it matters. Consistent venting practice is standard in congenital heart CPB to prevent distension and facilitate protection—especially in collateralized circulations [9, 10].

4) Perfusion strategy: flow, hematocrit, and pressure

Principle. In neonates/infants, oxygen delivery (DO₂) is safeguarded by higher pump flows and avoiding severe hemodilution. Multiple pediatric series and a practice review support “high-flow, high-hematocrit” strategies (e.g., flows ≈200 mL/kg/min in neonates; on-pump hematocrit ≥32%) with low rates of acute kidney injury and early neurological events when paired with careful monitoring [2, 15].

Practical targets.

• Flows: neonates around 200 mL/kg/min; young infants often 150–175 mL/kg/min; adjust for collateral burden and real-time markers of perfusion (NIRS trends, lactate, venous saturation) [2].
• Hematocrit: ≥30–32% on CPB; avoid extreme hemodilution, which has the strongest evidence base among neuroprotective measures in infants [1, 2].
• MAP: maintain age-appropriate pressures (often ≥30–40 mmHg in neonates) to support CBF and systemic perfusion, particularly under deeper hypothermia or significant runoff [5].

Why it matters. Higher flow + higher Hct preserves DO₂ and correlates with low observed early neurologic/renal injury; conversely, hemodilution is linked to worse neurocognitive risk in systematic review [1, 2, 15].

5) Anticoagulation in high-hematocrit, cyanotic patients

Principle. Polycythemia reduces plasma volume and lowers antithrombin (AT) activity, predisposing to heparin resistance (inadequate ACT/anti-Xa despite dosing). Infants also have immature coagulation systems.

What to do.

• Screen for heparin resistance: baseline labs (AT activity if available), early ACT response, consider anti-Xa monitoring and heparin dose-response (HMS/PSCB) methods rather than ACT alone in infants.
• If ACT/anti-Xa goals are not achieved, supplement AT (preferred) or use FFP in the prime, then re-check response.
• Use individualized heparin/protamine protocols; RCT data in infants show better anticoagulation profiles and improved clinical metrics with individualized management versus weight-based dosing [13–14].

Why it matters. Low AT correlates with reduced heparin efficacy and increased thrombin generation; individualized, concentration-guided anticoagulation outperforms weight-based strategies in infants [12–14].

Practical checklist

• Before CPB: document baseline NIRS; place an LA/LV vent; review hematocrit/AT and anticipate heparin needs; plan staged gas normalization (controlled reoxygenation).
• During CPB: raise PaO₂/normalize PaCO₂ gradually; tolerate mild hypercarbia to mitigate AP steal; maintain age-appropriate MAP; watch rSO₂ trends, venous oximetry, lactate, and urine output; avoid extreme hemodilution [1–3].
• After CPB: expect reactive hyperemia and a tendency to pulmonary overcirculation; use gentle ventilation, diuretics as needed, and reassess collateral impact on systemic perfusion.

References

[1] Hirsch JC, Jacobs ML, Andropoulos D, et al. Protecting the infant brain during cardiac surgery: a systematic review. Ann Thorac Surg. 2012;94(4):1365-1373.

[2] Ramakrishnan K, Kumar TS, Boston US, Allen J, Knott-Craig CJ. Cardiopulmonary bypass in neonates and infants: advantages of high-flow, high-hematocrit bypass strategy—clinical practice review. Transl Pediatr. 2023;12(7):1431-1438.

[3] Beshish AG, Jahadi O, Mello A, et al. Hyperoxia during cardiopulmonary bypass is associated with mortality in infants undergoing cardiac surgery. Pediatr Crit Care Med. 2021;22(5):445-453.

[4] Sznycer-Taub N, Peng YW, Yu S, et al. Perioperative normoxia versus hyperoxia in neonates with cyanotic heart disease undergoing cardiac surgery: a randomized controlled trial. Ann Thorac Surg. 2025;Epub ahead of print.

[5] Greeley WJ, Ungerleider RM, Kern FH, et al. Effects of cardiopulmonary bypass on cerebral blood flow in neonates, infants, and children. Circulation. 1989;80(3 Pt 1):I209-I215.

[7] Margetson TD. Perfusion methods and modifications to the cardiopulmonary bypass circuit for surgery in children—A review. Ann Med Surg (Lond). 2019;48:61-67.

[8] Mainwaring RD, MacDonald ST, Palmon M, et al. Measurement of residual collateral flow in pulmonary atresia with major aortopulmonary collaterals. Ann Thorac Surg. 2019;107(4):1116-1122.

[9] Kumar TK, Zurakowski D, Muralidaran A, et al. Practical conduct of open-heart procedures for congenital heart disease: perfusion considerations. J Thorac Dis. 2020;12(5):2478-2496.

[10] Kumar V, Turek JW. Cardiopulmonary Bypass. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.

[13] Gruenwald CE, McCrindle BW, Crawford-Leapord D, et al. Randomized, controlled trial of individualized heparin and protamine management in infants undergoing cardiac surgery with cardiopulmonary bypass. J Am Coll Cardiol. 2010;56(11):882-890.

[14] Harnish J, Beyer K, Collins J. Anticoagulation strategies in pediatric cardiopulmonary bypass: weight-based vs concentration-based approaches. J Extra Corpor Technol. 2022;54(2):153-160.

[15] Chakraborty A, Ramakrishnan K, Buyukgoz C, et al. Incidence of acute neurological events in neonates and infants undergoing cardiac surgery using a high-hematocrit/high-flow bypass strategy. World J Pediatr Congenit Heart Surg. 2023;14(3):375-379.